ClinicalTrials.gg
Drug

Fezolinetant clinical trials

Also written ESN364 and VEOZAH™.

studies test it
27
open now
7
in phase 3
12
first study started
2015

How each study uses fezolinetant is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the fezolinetant studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
12 May 2023 · VEOZAH · NDA 216578 (FDA, Drugs@FDA)
European Union
7 Dec 2023 · Veoza · EMEA/H/C/005851 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Fezolinetant
25

Brand

VEOZAH™
7

Development codes

ESN364
18
ASP2693
1

Studies by the year they started

27 studies that test it; most in 2020 (6)

Studies that test fezolinetant, by start year
YearStudies
20151
20171
20181
20193
20206
20213
20244
20253
20265

By phase

A phase 1/2 study counts in both.

Phase 1
7
Phase 2
9
Phase 3
12

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 21 · Other 6

Astellas Pharma Global Development, Inc. (12) · Astellas Pharma Inc (5) · Astellas Pharma China, Inc. (3) · Ogeda S.A. (1) · Rebecca Thurston (1) · University of Colorado, Denver (1) · Yale University (1) · Chinese University of Hong Kong (1)

Often tested with

Tested in the same studies.

Semaglutide (1) · Hormone Therapy (1) · Enzalutamide (1) · Apalutamide (1) · Bicalutamide (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2

Studies that test fezolinetant.

Studies

Open first, then newest update. How each study uses fezolinetant is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 27

See all 27 studies that test fezolinetant →

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call fezolinetant · ClinicalTrials.gg INT000489

  • MeSH (NLM) C000608808fezolinetantConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 83VNE45KXXFEZOLINETANTConfirmed FDA, NLM, Wikidata
  • Wikidata Q27269455fezolinetantConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C171845FezolinetantOne source FDA
  • DrugBank DB15669One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.